Navigation Links
InBios Obtains BARDA Funding to Develop Point-of-Care COVID-19 Test

InBios International Inc., a leading developer of diagnostic tests for emerging infectious diseases, announced today that it had been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to develop the SCoV-2 Detect IgM/IgG Rapid Test, a point-of-care test for detection of SCoV-2 specific IgM/IgG antibodies.

The lateral flow serodiagnostic test will use blood products, from finger-prick samples, to identify people infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. This point-of-care assay will detect SARS-CoV-2 reactive antibodies as host biomarkers.

Under the agreement, InBios will acquire reagents, including patient samples, develop product kits and carry out performance studies to validate the assay design for Emergency Use Authorization (EUA) submission to the U.S. Food and Drug Administration (FDA). Support from BARDA is expected to accelerate the progress toward EUA submission. Earlier this month, InBios received EUA for its Smart DetectTM SARS-CoV-2 rRT-PCR Kit.

“As we all know, time is of the essence during this pandemic, and a robust serological test is needed to quickly and easily identify symptomatic, as well as high-risk asymptomatic, individuals who can be carriers responsible for a large percentage of person-to-person transmission,” said Dr. Syamal Raychaudhuri, InBios’ chief scientific officer. “This funding from BARDA enables InBios to rapidly mobilize to develop this test for the EUA purpose.”

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract No. 75A50120C00090.

For more information about InBios COVID-19 tests, visit:

For more information on COVID-19, please visit or

About InBios: InBios International Inc. specializes in the design, development and manufacture of diagnostic devices for emerging infectious diseases and biothreats. Founded in 1996 in Seattle, WA, our superior quality products are accurate, easy to use and cost effective. InBios offers an extensive catalog of life science reagents, along with a portfolio of more than 25 diagnostic products, including an FDA Emergency Use Authorization for our Smart DetectTM SARS-CoV-2 rRT-PCR Kit and FDA-cleared ELISA kits for Zika, dengue, and West Nile and rapid test kits for Chagas and leishmaniasis. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved

Related biology news :

1. Spanish scientist obtains international award for 3-D video of a journey to the interior of a cicada
2. Law Firm Carey Rodriguez Obtains First-Of-Its-Kind Ruling In Landmark Biometric Privacy Case
3. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract and Increase Funding for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
4. 4 projects awarded Discovery Transformation Grant funding by Minnesota Partnership
5. Funding for animal testing alternative
6. Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014
7. UTSA chemist awarded $300,000 in NASA funding to build lab on a robot prototype
8. Geneticists receive funding to improve citrus production and health
9. 83 global health innovations receive Grand Challenges Canada funding
10. NIH director warns that US research funding is falling behind, calls for new focus on innovation
11. BBSRC announces £10M of funding for advanced scientific equipment
Post Your Comments:
(Date:5/14/2020)... (PRWEB) , ... May 14, 2020 , ... ... job board for medical sales representatives, found the 2019 average medical sales rep ... findings risk being shadowed by uncertainties amid the COVID-19 global crisis. , The ...
(Date:5/1/2020)... ... 30, 2020 , ... Flagship Biosciences , providers of ... biopharmaceutical and regulatory services advisor. The companies now deliver regulatory strategy and support ... taking a collaborative approach to empower more confident and informed regulatory decisions through ...
(Date:4/30/2020)... , ... April 29, 2020 , ... ... positioned for continued growth – delivering innovative solutions for a wide range of ... aerospace and government agencies. A month into the new decade, it was clear ...
Breaking Biology News(10 mins):
(Date:5/30/2020)... ... May 29, 2020 , ... The Conference Forum ... newsletter solely dedicated to the unique role of the Chief Medical Officer in ... the responsibilities, problem-solving, best practices and career development of CMOs and Heads of ...
(Date:5/21/2020)... , ... May 21, 2020 , ... ... clinical trials will cause long-term harm , Contrary to conventional wisdom that says ... study finds many companies will emerge from the pandemic commercially weaker, dealing ...
(Date:5/15/2020)... ... May 14, 2020 , ... ... (hMSC) working cell banks and hMSC bioprocess systems, today announced the launch ... of hMSC-derived extracellular vesicles (EVs). RoosterCollect™-EV-CC is the only system designed with ...
(Date:5/14/2020)... ... May 12, 2020 , ... DuPont Nutrition ... distribution partner for all personal care ingredients in Russia and Belarus. Beginning May ... preservative portfolio for personal care. , The GENENCARE®OSMS product line contains ...
Breaking Biology Technology: